Orlistat for obesity: Benefits beyond weight loss

Diabetes Research and Clinical Practice

Volumn 67, Issue 1, 2005, Pages 78-83

  Hsieh, Ching Jung ^a   Wang, Pei Wen ^a   Liu, Rue Tsuan ^a   Tung, Shih Chen ^a   Chien, Wen Yen ^a   Chen, Jung Fu ^a   Chen, Chen Hsiong ^a   Kuo, Ming Chun ^a   Hu, Ya Hui ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Adiponectin; C reactive protein; Leptin; Obesity; Orlistat

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; INSULIN; LEPTIN; TETRAHYDROLIPSTATIN;

ADULT; AGE DISTRIBUTION; ARTICLE; ATHEROSCLEROSIS; BODY FAT; BODY MASS; BODY WEIGHT DISORDER; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC OBESITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEALTH PROGRAM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OBESITY; PROTEIN BLOOD LEVEL; SEX RATIO; STATISTICAL SIGNIFICANCE; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; ARTERIOSCLEROSIS; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LACTONES; LIPOPROTEINS; MALE; MIDDLE AGED; OBESITY; WEIGHT LOSS;

EID: 11144317915     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2004.05.012     Document Type: Article

References (23)

1. Hollander P.A., Elbein S.C., Hirsch I.B., et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care. 21:1998;1288-1294
2. Rosenfalck A.M., Hendel H., Rasmussen M.H., et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and β-cell function in obese subjects, diabetes. Obes. Metab. 4:2002;19-28
3. Karhunen L., Franssila-Kallunki A., Rissanen P., et al. Effect of Orlistat treatment on body composition and resting energy expenditure during a 2-year weight-reduction program in obese Finns. Int. J. Obes. 24:2000;1567-1572
4. Rodrigues A.M., Radominski R.B., Suplicy H.L., Almeida S.M., Niclewicz P.A., Boguszewski G.L. The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity. J.Clin. Endocrinol. Metab. 87:2002;1621-1626
5. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86:2001;1930-1935
6. Rifai N., Ridker P.M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin. Chem. 47:2001;403-411
7. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. a statement for healthcare professionals from the centers for disease control and prevention and the american heart association. Circulation. 107:2003;499-511
8. Tchernof A., Nolan A., Sites C.K., Ades P.A., Poehlman E.T. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 105:2002;564-569
9. Flether G.F., Balady G., Blair S.N. Statement on exercise: benefits and recommendations for physical activity programs for all Americans. Circulation. 94:1996;857-862
10. Hauptman J., Lucas C., Boldrin M.N., Collins H., Segal K.R. Orlistat in the long-term treatment of obesity in primary care settings. Arch. Fam. Med. 9:2000;160-167
11. Davidson M.H., Hauptman J., DiGirolamo M., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA. 281:1999;235-242
12. Ballinger A., Peikin S.R. Orlistat: its current status as an anti-obesity drug. Eur. J. Pharmacol. 440:2002;109-117
13. Torgerson J.S., Hauptman J., Boldrin M.N., SjA strA m L. XENical in the Prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 27:2004;155-161
14. Reaven G., Karen S., Jonathan H., Mark B., Charles L. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome-X. Am. J. Cardiol. 89:2001;827-831
15. Russell P.T. Is visceral adiposity the "enemy within"? Arterioscler. Thromb. Vasc. Biol. 21:2001;881-883
16. Lemieux I., Pascot A., Prudhomme D., et al. Elevated c-reactive protein another component of the atherothrombotic profile of abdominal obesity. Arterioscler. Thromb. Vasc. Biol. 21:2001;961-967
17. Rifai N., Ridker P.M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin. Chem. 47:2001;403-411
18. Clement K., Vaisse C., Lahlou N., et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 392:1998;398-401
19. Halaas J.L., Gajiwala K.S., Maffei M., et al. Weight-reducing effects of the plasma proteins encoded by the obese gene. Science. 269:1995;543-546
20. Matsubara M., Maruoko S., Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur. J. Endocrinol. 147:2002;178-180
21. Hu E., Liang P., Spiegelman B.M. AdipoQ is a novel adipocytes-specific gene dysregulated in obesity. J. Biol. Chem. 71:1996;10697-10703
22. Ouchi N., Kihara S., Artia Y. et al. Novel modulator for endothelial adhesion molecules: adipocytes-derived plasma protein adiponectin. Circulation. 100:1999;2473-2476
23. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinolo. Metab. 86:2001;1930-1935